abbv

AbbVie's Schizophrenia Failure Disappoints But Analysts Show Confidence In Immunology Portfolio




abbv

AbbVie Drug Expected to Rival Bristol Myers’s New Schizophrenia Med Flunks Phase 2 Test

AbbVie schizophrenia drug candidate emraclidine failed to beat a placebo in two Phase 2 clinical trials. The drug, once projected to compete with Bristol Myers Squibb’s Cobenfy, is from AbbVie’s $8.7 billion acquisition of Cerevel Therapeutics.

The post AbbVie Drug Expected to Rival Bristol Myers’s New Schizophrenia Med Flunks Phase 2 Test appeared first on MedCity News.




abbv

AbbVie invests in switchable CAR-T therapies for cancer

The drug company is partnering with Calibr to develop universal CAR T-cells directed to different tumors via antibody switches




abbv

AbbVie invests in switchable CAR-T therapies for cancer

The drug company is partnering with Calibr to develop universal CAR T cells directed to different tumors via antibody switches




abbv

Calico and AbbVie advance antiaging efforts




abbv

AbbVie: Redeploy The Allergan Cash




abbv

US regulators permit AbbVie/Allergan merger

The closing of the acquisition remains subject to other customary closing conditions




abbv

Ayala hires AbbVie’s Gary Gordon as new CMO

AbbVie’s former Vice President of Oncology has moved to Ayala Pharmaceuticals to work as its new Chief Medical Officer (CMO). 

Israel-based startup Ayala Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing targeted cancer therapies for people living with genetically defined cancers – it is currently working on the development of its pan-Notch inhibitor AL101, currently in Phase 2 in adenoid cystic carcinoma (ACC).

read more




abbv

FTC clears AbbVie’s $63bn Allergan takeover

US regulator satisfied that antitrust concerns are remediated




abbv

US FTC clears AbbVie’s buy of Allergan, but with divestments

Almost a year after the original announcement, the US Federal Trade Commission (FTC) has accepted the…



  • AbbVie/Allergan/Companies
  • mergers and acquisitions/Endocrinology/Federal Trade Commission/Ireland/Legal/Management/Pancrelipase/Pharmaceutical/USA/Viokace/Zenpep

abbv

BRIEF—AbbVie finally completes acquisition of Allergan

US pharma major AbbVie has finally completed its $63 billion acquisition of Ireland-incorporated Allergan,…



  • AbbVie/Allergan/Companies
  • mergers and acquisitions/Ireland/Legal/Pharmaceutical/USA

abbv

AbbVie CEO: Don't worry, Allergan's aesthetics clients still have money—and 'strong desire' for treatment

AbbVie may be working through COVID-19, but it's pressing ahead with its Allergan merger, too—and taking stock of products hit by pandemic lockdowns. That puts Allergan’s aesthetics business top of mind, but AbbVie CEO Rick Gonzalez figures customers are ready and able to return quickly for treatment.




abbv

AbbVie, Allergan score FTC approval for $63B merger with one final hurdle left to go

AbbVie and Allergan have waited for nearly a year for their much-discussed merger to pass muster. Finally, after pushback from consumer groups and tight scrutiny from regulators, the FTC has granted its green light. The partners face just one final hurdle to consummating their deal. 




abbv

US regulator clears AbbVie’s $63bn deal for Allergan

Federal Trade Commission votes 3-2 to approve tie-up between makers of Botox and Humira




abbv

AbbVie invests in switchable CAR-T therapies for cancer

The drug company is partnering with Calibr to develop universal CAR T-cells directed to different tumors via antibody switches




abbv

AbbVie invests in switchable CAR-T therapies for cancer

The drug company is partnering with Calibr to develop universal CAR T cells directed to different tumors via antibody switches




abbv

Calico and AbbVie advance antiaging efforts